Bernadette Connaughton Sells 1,625 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25.
• On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $79.45 on Friday. The stock has a market capitalization of $9.42 billion, a price-to-earnings ratio of 28.58, a PEG ratio of 0.33 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 52 week low of $53.33 and a 52 week high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The firm has a 50 day moving average of $69.41 and a 200 day moving average of $69.42.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Measured Wealth Private Client Group LLC boosted its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Harbour Investments Inc. raised its holdings in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the last quarter. Clearstead Advisors LLC lifted its position in Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 331 shares during the period. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics during the third quarter valued at $70,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HALO has been the topic of a number of recent analyst reports. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.